Quantification of Immune Cells in Women Using Contraception (CHIC II)
Information source: University of Pittsburgh
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV; Immune Cells (Mucosal and Systemic); Contraception
Intervention: levonorgestrel exposure (Drug); DMPA exposure (Drug); etonogestrel exposure (Drug); IUD insertion (Device); subdermal contraceptive implant insertion (Device)
Phase: N/A
Status: Recruiting
Sponsored by: University of Pittsburgh Official(s) and/or principal investigator(s): Sharon Achilles, MD, PhD, Principal Investigator, Affiliation: University of Pittsburgh
Overall contact: Melissa Fann, MPH, Phone: 412-641-5187, Email: gilmoremn@upmc.edu
Summary
This study is being done to understand if using birth control causes changes in the immune
cells within the reproductive tract (including the cervix and the lining of the uterus) of
healthy women. Immune cells are important because they help prevent infections from starting
and help fight infections that have started. Immune cells are also the type of cells that
HIV (human immunodeficiency virus) infects so understanding more about them will help to
better understand how to prevent the spread of HIV.
Immune cells will be studied from the reproductive tract of women who want to start using
one of the following contraceptives: an oral contraceptive pill (COC), Depo-Provera (DMPA),
the levonorgestrel IUD (Mirena®), the copper IUD (ParaGard®), or the etonogestrel subdermal
implant (Nexplanon®).Immune cells will also be studied from the reproductive tract of women
who are not using birth control and who are not at risk of pregnancy for comparison.
Clinical Details
Official title: Quantification of Immune Cells in Women Using Contraception
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Quantification and characterization of immune cell populations and HIV-tropic receptor expression
Secondary outcome: Assessing changes in the vaginal microflora within the first 6 months of contraceptive use
Eligibility
Minimum age: 18 Years.
Maximum age: 34 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
1. Age 18 through 34 years (inclusive) at screening
2. Non-pregnant women in general good health as determined by the site clinician
3. Premenopausal with history of regular menstrual cycles (regular cycles defined as
occurring every 21-35 days when not using hormones and with a variation of typical
cycle length of no more than 5 days)
4. Women enrolling into the control group only: Regular and consistent condom use, prior
surgical sterilization by participant or sexual partner, or heterosexually abstinent
for entire study participation
5. Able and willing to provide written informed consent to be screened for and to take
part in the study. Including willingness to undergo all study-related assessments and
follow all study-related procedures
6. Able and willing to provide adequate locator information
7. HIV-uninfected based on testing performed by study staff at screening (per HIV
testing algorithm in Appendices I)
8. At screening and enrollment, agrees not to participate in other research studies
involving drugs, medical devices, or vaginal products while enrolled in this trial
Exclusion Criteria:
1. Use of any hormonal or intrauterine contraceptive method within 30 days of enrollment
2. Use of DMPA within 10 months of enrollment
3. Pregnancy or breastfeeding within 60 days of enrollment
4. Surgical procedure involving the pelvis in the 30 days prior to enrollment (includes
dilation and curettage, cryosurgery and biopsy of the vagina, vulva, cervix, and
endometrium)
5. Internal vaginal use of any device (includes sex toys, cervical caps, diaphragms,
menstrual collection devices, and pessaries; excludes tampons and condoms) or product
(includes N9, microbicide, douche, antifungal, steroid, or hormone) in the 30 days
prior to enrollment
6. New sexual partner within 90 days of enrollment
7. Urogenital infection or suspected infection within 30 days of enrollment including:
symptomatic candidiasis, trichomonas vaginalis, and symptomatic bacterial vaginosis;
or cervical infection, including N. gonorrhea, C. trachomatis, or mucopurulent
cervicitis; syphilis; HSV lesions, or other sores (Note: seropositive HSV without
active lesions will not be excluded); acute pelvic inflammatory disease; urinary
tract infection; recent exposure to a partner with GC, CT, Trichomonas, syphilis, or
NGU
8. Any history of immunosuppression (includes diabetes, HIV infection, and chronic
steroid use)
9. Antibiotic or antifungal therapy (vaginal or systemic) within 30 days of enrollment
10. Menses or other vaginal bleeding at the time of Enrollment* (*Women who have vaginal
bleeding at the scheduled Enrollment Visit may return at a different date to be
re-examined and possibly enrolled provided they are still within the 90-day screening
window and meet all criteria).
11. Vaginal or anal intercourse within 36 hours prior to enrollment
12. Heterosexual intercourse since last menses that places the participant at risk of
pregnancy (without condom use or sterilization of at least one partner)
13. History of hysterectomy
14. History of malignancy within the pelvis (includes uterus, cervix, vagina, and vulva)
15. Contraindication, allergy or intolerance to use of the contraceptive desired by the
participant
16. Any condition that, in the opinion of the Investigator, would preclude provision of
consent, make participation in the study unsafe, complicate interpretation of study
outcome data, or otherwise interfere with achieving the study objectives
Locations and Contacts
Melissa Fann, MPH, Phone: 412-641-5187, Email: gilmoremn@upmc.edu
Center for Family Planning Research, Pittsburgh, Pennsylvania 15213, United States; Recruiting Sabrina Malik, MPH, Phone: 412-641-8257, Email: maliks2@upmc.edu Melissa Gilmore, MPH, Phone: 412-641-5187, Email: gilmoremn@upmc.edu Sharon Achilles, MD, PhD, Principal Investigator
Additional Information
Starting date: August 2013
Last updated: July 15, 2015
|